Published in Cancer Weekly, January 8th, 2002
The new agreement with Duke consolidates Conforma's position in the field of heat shock protein-90 (HSP90)-directed drugs. Under the agreement, Conforma obtains from Duke an exclusive license to novel screening technology, x-ray crystal structure information useful in the rational design of drugs directed against individual HSP90 family members, and a proprietary target for drug discovery.
In addition, under a sponsored research agreement, Conforma has initiated a research collaboration in the field of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.